Wuxi Apptec Stock Price, News & Analysis

WuXi AppTec (WUXAY), a global pharmaceutical and life sciences technology platform company, has released a positive profit alert for H1 2025. The company expects total revenue of RMB20.80 billion, up 20.6% year-over-year, with revenue from Continuing Operations growing 24.2%.

Key financial highlights include an expected adjusted non-IFRS net profit of RMB6.31 billion (up 44.4% YoY), net profit after non-recurring items of RMB5.58 billion (up 26.5% YoY), and net profit attributable to owners of RMB8.56 billion (up 101.9% YoY). Basic earnings per share is projected at RMB3.01, representing a 106.2% increase.

WuXi AppTec (WUXAY) has completed significant share repurchase and acquisition activities in Q2 2025. The company executed an RMB1.0 billion A-share repurchase program, buying back 15,775,377 A-shares at RMB63.39 per share (0.55% of total shares) between April 18 and June 20, 2025, which were subsequently cancelled on June 24.

Additionally, the company acquired HKD2.5 billion worth of H-shares (34,092,975 shares, 1.19% of total shares) through its 2025 H Share Award and Trust Scheme. The H-share acquisition is tied to revenue targets, with HKD1.5 billion in shares to be granted if 2025 revenue reaches RMB42.0 billion, and an additional HKD1.0 billion if revenue hits RMB43.0 billion.

WuXi AppTec (WUXAY) has achieved the highest possible MSCI ESG rating of AAA, becoming the first A-share listed company in the life science industry to reach this milestone. The company earned this distinction for excellence in Product Safety and Quality, Human Capital Development, and Corporate Governance, upgrading from its previous AA rating maintained for four consecutive years.

The achievement is complemented by WuXi AppTec's other sustainability recognitions, including four consecutive years in the Dow Jones Sustainability Index, A- Leadership rating in CDP Climate Change assessment, and Gold Medal in EcoVadis sustainability rating. The company has also received validation from the Science Based Targets initiative (SBTi) for its emissions reduction targets and participates in the UN Global Compact.

WuXi AppTec (OTC:WUXAY), a global provider of R&D and manufacturing services for the pharmaceutical industry, announced that its Nantong site (Phase I) has won the Popular Choice Winner award in the "Factory & Warehouse" category at the 2025 Architizer A+Awards.

The Nantong site, located in Jiangsu province, China, features eight main buildings arranged in two clusters and serves as a key component of WuXi AppTec's CRDMO platform. The facility's design emphasizes 'technological-humanistic symbiosis', incorporating operational efficiency with human-centered design elements. The site provides comprehensive chemistry, biology, and testing solutions to global customers.

WuXi AppTec (WUXAY) has received validation from the Science Based Targets initiative (SBTi) for its near-term emissions reduction targets, demonstrating alignment with global efforts to limit temperature rise to 1.5°C. The company commits to reducing absolute Scope 1 and 2 GHG emissions by 42% by 2030 from 2024 levels, and Scope 3 emissions from purchased goods and services by 25%. To achieve these targets, WuXi AppTec is implementing various measures including process optimization, equipment upgrades, infrastructure renovation, and increasing renewable energy usage. The company has garnered multiple sustainability recognitions, including an AA rating in MSCI ESG ratings, inclusion in the Dow Jones Sustainability Index, and an A- Leadership rating in CDP Climate Change rating. As a global provider of R&D and manufacturing services for pharmaceutical and life science industries, WuXi AppTec has also joined the UN Global Compact and Pharmaceutical Supply Chain Initiative.

WuXi AppTec (WUXAY) has been named among the Top 10 'Most Honored Companies' in Extel's 2025 Asia Executive Team Rankings, selected from over 1,600 companies across 18 industries. The company secured first-place rankings in multiple Healthcare, Pharma & Biotech sector categories, including Best CEO, CFO, Company Board, IR Program, and ESG Program. The recognition comes from a comprehensive survey involving more than 6,300 portfolio managers and analysts from 1,324 institutions. WuXi AppTec's Contract Research, Development and Manufacturing Organization (CRDMO) model continues to drive business growth by providing integrated support across drug development processes, reducing research and deployment costs while maintaining high-quality standards.

WuXi AppTec (WUXAY) reported strong Q1 2025 financial results with total revenue reaching RMB9.65 billion, up 21.0% year-over-year. Revenue from continuing operations increased 23.1% to RMB9.39 billion.

Key highlights include:

• Net profit attributable to owners reached RMB3.67 billion, up 89.1% YoY
• Adjusted non-IFRS net profit grew 40.0% YoY to RMB2.68 billion
• Backlog for continuing operations increased 47.1% YoY to RMB52.33 billion
• Operating cash flow improved 41.8% YoY to RMB3.03 billion

The company's CRDMO platform showed strong performance, with WuXi Chemistry segment revenue up 32.9% YoY and TIDES revenue growing 187.6% YoY. Management maintains its 2025 guidance of 10-15% revenue growth from continuing operations.

WuXi AppTec announced that its Active Pharmaceutical Ingredient (API) manufacturing sites in Changzhou and Taixing, China, have successfully passed U.S. FDA inspections in March 2025 with no observations or Form 483 issues.

The Changzhou facility's GMP surveillance inspection covered 21 FDA-approved products, while Taixing completed a Pre-Approval Inspection for commercial manufacturing of a peptide-based therapeutic. The 169-acre Taixing site, operational since September 2023, is the company's newest and largest API manufacturing facility.

WuXi AppTec is expanding globally with recent developments including:

• Doubled oral dose capacity at Couvet, Switzerland facility in 2024
• Ongoing construction of Middletown, Delaware site (operations expected by 2026)
• New Singapore R&D and manufacturing site groundbreaking (Phase I operations planned for 2027)

WuXi AppTec reported strong financial results for 2024, with Q4 revenue reaching RMB11,539 million (up 6.9% YoY) and full-year revenue of RMB39,241 million (up 5.2% YoY excluding COVID-19 projects). Key highlights include:

- Net profit of RMB9,450 million with diluted EPS of RMB3.26
- Record-high free cash flow of RMB7.98 billion
- Backlog growth of 47% YoY reaching RMB49.31 billion
- ~6,000 active customers with ~1,000 new additions in 2024

The company's CRDMO platform showed significant growth with 1,187 new molecules added in 2024, bringing the total pipeline to 3,377 molecules. Global expansion continues with new facilities in Switzerland, Delaware (US), and Singapore. For 2025, WuXi AppTec projects 10-15% YoY revenue growth, targeting RMB41.5-43.0 billion, and announces plans for increased shareholder returns through dividends and share buybacks.